U.S. Need For Biotech Generic Drugs Seen As Boon For China
This article was originally published in PharmAsia News
Executive Summary
Drug policy pressures on the United States could have an ancillary effect of making more Chinese drug firms bigger players in the world market, one expert believes. Dr. Jim Wei, a former senior reviewer for the U.S. FDA and now director of clinical pharmacology at the contract research organization Medpace, says the pressure on the United States to lower drug prices encourages foreign drug makers to enter the market for generic drugs. He said that situation is leading to an increase in the need for generic protein drugs, an area of biotech drugs where the legality of copying is hazy in the United States. As the demand rises, "Chinese manufacturers have the ability to produce such products," Wei says. (Click here for more